← Leaderboards
Holly Janes
Fred Hutchinson Cancer Center
$70,932,400
Attributed
$203,415,905
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $48.4M · FY2010–25$50M$37.5M$25M$12.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$203,415,905 · 4
By mechanism
UM1$198,520,190 · 1
R01$3,806,368 · 1
R56$815,923 · 1
R21$273,424 · 1
Top collaborators
- Peter B. Gilbert27 shared
- Yunda Huang27 shared
- Genevieve Giny Fouda Amou Ou1 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Peter B. Gilbert$223,972,501
- Yunda Huang$75,372,842
- Margaret Juliana McElrath$601,692,649
- Lawrence Corey$859,232,520
- Georgia D Tomaras$127,423,185
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignProtocols DocumentationPreventionEfficacy TrialVaccinesLaboratoriesProgramsVaccine TrialHiv Vaccine Trials NetworkLeadershipBiometryImmuneImmune ResponseBasePreventParticipantClinical Trials NetworkClinical TrialsHiv VaccineInfectionImmune FunctionOperationResponseImmunology
Grant awards (42)
SDMC: HIV Vaccine Trials Network$35,817,302
UM1 · FY2025 · AI
SDMC: HIV Vaccine Trials Network$4,411,693
UM1 · FY2025 · AI
SDMC: HIV Vaccine Trials Network$992,886
UM1 · FY2025 · AI
SDMC: HIV Vaccine Trials Network$991,756
UM1 · FY2025 · AI
Defining and modeling HIV-1-specific antibody function in HIV-1-exposed Infants passively Infused with broadly neutralizing antibodies in the IMPAACT P1112 trial.$273,424
R21 · FY2025 · HD
SDMC: HIV Vaccine Trials Network$31,992,488
UM1 · FY2024 · AI
B Cell Bioinformatic Supplement: HIV Vaccine Trials Network (HVTN)$330,961
UM1 · FY2024 · AI
SDMC: HIV Vaccine Trials Network$28,510,098
UM1 · FY2023 · AI
CoVPN 3008 2022-2023$12,647,369
UM1 · FY2023 · AI
SDMC: HIV Vaccine Trials Network$21,460,272
UM1 · FY2022 · AI
SDMC: HIV Vaccine Trials Network$5,436,127
UM1 · FY2022 · AI
CoVPN Cross-Protocol Analyses$1,846,794
UM1 · FY2022 · AI
CoVPN Cross-Protocol Analyses$1,334,886
UM1 · FY2022 · AI
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals$1,011,819
UM1 · FY2022 · AI
CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection$818,451
UM1 · FY2022 · AI
CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection SDMC$477,868
UM1 · FY2022 · AI
CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine$453,649
UM1 · FY2022 · AI
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.$439,437
UM1 · FY2022 · AI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older$419,442
UM1 · FY2022 · AI
CoVPN 3002 - A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study in Adults to Determine the safety, Efficacy, and Immunogenicity of AZD1222 for Prevention of Covid-19$318,803
UM1 · FY2022 · AI
HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals$293,711
UM1 · FY2022 · AI
CoVPN 3003 - A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older SDMC$260,795
UM1 · FY2022 · AI
CoVPN 3004 A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a SARS-CoV-2 Spike Protein Nanoparticle Vaccine in Adults$234,860
UM1 · FY2022 · AI
Statistical Methods for Evaluating and Guiding Implementation of New HIV Prevention Strategies$41,105
R56 · FY2022 · AI · contact PI
SDMC: HIV Vaccine Trials Network$26,398,527
UM1 · FY2021 · AI
CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older SDMC$18,322,345
UM1 · FY2021 · AI
CoVPN 3006: A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine$2,034,708
UM1 · FY2021 · AI
CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection SDMC$673,501
UM1 · FY2021 · AI
CoVPN Cross-Protocol Analyses$589,642
UM1 · FY2021 · AI
Statistical Methods for Evaluating Markers for Treatment Selection$358,007
R01 · FY2021 · CA · contact PI
Statistical Methods for Evaluating Markers for Treatment Selection$71,331
R01 · FY2021 · CA · contact PI
Statistical Methods for Evaluating Markers for Treatment Selection$429,338
R01 · FY2020 · CA · contact PI
Statistical Methods for Evaluating and Guiding Implementation of New HIV Prevention Strategies$774,818
R56 · FY2019 · AI · contact PI
Statistical Methods for Evaluating Markers for Treatment Selection$416,457
R01 · FY2019 · CA · contact PI
Statistical Methods for Evaluating Markers for Treatment Selection$429,338
R01 · FY2018 · CA · contact PI
Statistical Methods for Evaluating Markers for Treatment Selection$429,338
R01 · FY2017 · CA · contact PI
Statistical Methods for Evaluating Markers for Treatment Selection$376,785
R01 · FY2015 · CA · contact PI
Statistical Methods for Evaluating Markers for Treatment Selection$366,952
R01 · FY2014 · CA · contact PI
Statistical Methods for Evaluating Markers for Treatment Selection$356,929
R01 · FY2013 · CA · contact PI
Statistical Methods for Evaluating Markers for Treatment Selection$25,051
R01 · FY2012 · CA · contact PI
Statistical Methods for Evaluating Markers for Treatment Selection$381,025
R01 · FY2011 · CA · contact PI
Statistical Methods for Evaluating Markers for Treatment Selection$165,817
R01 · FY2010 · CA · contact PI